NYSE - Delayed Quote USD

Enzo Biochem, Inc. (ENZ)

1.0500 -0.0200 (-1.87%)
At close: April 26 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
7/31/2023
7/31/2022
7/31/2021
7/31/2020
Total Revenue
32,803.0000
31,061.0000
32,643.0000
117,731.0000
76,021.0000
Cost of Revenue
18,970.0000
19,495.0000
19,213.0000
64,154.0000
52,251.0000
Gross Profit
13,833.0000
11,566.0000
13,430.0000
53,577.0000
23,770.0000
Operating Expense
31,915.0000
31,106.0000
25,522.0000
52,885.0000
54,137.0000
Operating Income
-18,082.0000
-19,540.0000
-12,092.0000
692.0000
-30,367.0000
Net Non Operating Interest Income Expense
613.0000
-1,122.0000
178.0000
8.0000
454.0000
Other Income Expense
-5,846.0000
-4,360.0000
-8,425.0000
7,175.0000
1,393.0000
Pretax Income
-23,315.0000
-25,022.0000
-20,339.0000
7,875.0000
-28,520.0000
Net Income Common Stockholders
32,566.0000
20,288.0000
-18,261.0000
7,875.0000
-28,520.0000
Diluted NI Available to Com Stockholders
32,566.0000
20,288.0000
-18,261.0000
7,875.0000
-28,520.0000
Basic EPS
0.67
0.41
-0.38
0.16
-0.60
Diluted EPS
0.67
0.41
-0.38
0.16
-0.60
Basic Average Shares
49,966.0000
49,160.0000
48,594.0000
48,191.0000
47,696.0000
Diluted Average Shares
49,966.0000
49,160.0000
48,594.0000
48,325.0000
47,696.0000
Total Operating Income as Reported
-23,218.0000
-24,736.0000
-17,027.0000
692.0000
-30,367.0000
Total Expenses
50,885.0000
50,601.0000
44,735.0000
117,039.0000
106,388.0000
Net Income from Continuing & Discontinued Operation
32,566.0000
20,288.0000
-18,261.0000
7,875.0000
-28,520.0000
Normalized Income
-17,642.0000
-20,282.0000
-13,182.0000
7,605.0000
-29,425.0000
Interest Income
--
--
178.0000
--
--
Net Interest Income
613.0000
-1,122.0000
178.0000
8.0000
454.0000
EBIT
-18,082.0000
-19,540.0000
-12,092.0000
692.0000
-30,367.0000
EBITDA
-16,291.0000
-16,858.0000
-9,265.0000
3,345.0000
-27,587.0000
Reconciled Cost of Revenue
18,970.0000
19,495.0000
19,213.0000
64,154.0000
52,251.0000
Reconciled Depreciation
1,791.0000
2,682.0000
2,827.0000
2,653.0000
2,780.0000
Net Income from Continuing Operation Net Minority Interest
-23,315.0000
-25,022.0000
-20,339.0000
7,875.0000
-28,520.0000
Total Unusual Items Excluding Goodwill
-5,673.0000
-4,740.0000
-7,157.0000
270.0000
905.0000
Total Unusual Items
-5,673.0000
-4,740.0000
-7,157.0000
270.0000
905.0000
Normalized EBITDA
-10,618.0000
-12,118.0000
-2,108.0000
3,075.0000
-28,492.0000
7/31/2020 - 6/12/1980

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ERFSF Eurofins Scientific SE
60.00
-0.02%
 
CORBF Global Cord Blood Corporation
1.2500
0.00%
 
ACRS Aclaris Therapeutics, Inc.
1.2000
+0.84%
 
MYGN Myriad Genetics, Inc.
18.18
+1.11%
 
ERF.PA Eurofins Scientific SE
56.64
-1.50%
 
MYNZ Mainz Biomed N.V.
0.8181
-4.52%
 
VCYT Veracyte, Inc.
19.31
-0.87%
 
PRPH ProPhase Labs, Inc.
4.7100
-4.85%
 
NOTV Inotiv, Inc.
4.0500
-5.59%
 
LAB Standard BioTools Inc.
2.4400
+3.39%